Investigation of correlations between different prostate-specific antigen forms and clinical and morphological characteristics of a tumor process in patients with prostate cancer

Serum samples from 226 primary patients with prostate cancer (PC) and a baseline total prostate-specific antigen (t-PSA) of < 30.0 ng/ml were used to investigate f-PSA and [-2]proPSA levels and to calculate f-PSA%, [-2]proPSA%, and prostate health index (PHI). The findings were compared with cancer stage (pTNM) and Gleason grade (Gleason index) in accordance with a postoperative histological report. PHI was shown to have the best differentiating properties (pT2c/pT3a/pT3b; localized indolent PC / localized aggressive PC / locally advanced PC / PC with regional metastases; Gleason score 5-6 / Gleason score 7 (3+4) / Gleason score 7 (4+3).

1. Петрова Г. В., Каприн А. Д., Старинский В. В. и др. Заболеваемость злокачественными новообразованиями населения России. Онкология. Журнал им. П. А. Герцена 2014;5:5–10. [Petrova G. V., Kaprin A. D., Starinskiy V. V. et al. Incidence of malignant neoplasms in the population of Russia. Onkologiya. Jurnal im. P. A. Herzena. = P. A. Herzen. Journal of Oncology 2014;5:5–10. (In Russ.)].

2. Сергеева Н. С., Маршутина Н. В., Солохина М. П. и др. Современные представления о серологических опухолеассоциированных маркерах и их месте в онкологии. Успехи молекулярной онкологии 2014;(1):69–81. [Sergeeva N. S., Marshutina N. V., Solokhina M. P. et al. Modern conceptions of serological tumor markers and their role in oncology. Uspekhi molekulyarnoy onkologii = Advances in Molecular Oncology 2014;(1):69–81. (In Russ.)].

3. Mikolajczyk S.D., Marker K.M., Millar L.S. et al. A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res 2001;15; N 61(18):6958–63.

4. Mikolajczyk S. D., Catalona W. J., Evans C. L. et al. Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer. Clin Chem2004;50(6):1017–25.

5. Sokoll L. J., Wang Y., Feng Z. et al. [-2]ProPSA for prostate cancer detection: an NCI early detection research network validation study. J Urol 2008;180(2):539–43.

6. Catalona W. J., Partin A. W., Sanda M. G. et al. A Multi-Center Study of [-2]Proprostate- specific antigen (PSA) in combination with PSA and Free PSA for prostate cancer detection in the 2.0 to 10.0 ng/mL PSA Range. J Urol 2011;185(5):1650–5.

7. Lazzeri M., Haese A., Taille A. et al. Serum Isoform [S2] proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2–10 ng/ml: A Multicentric European Study. Eur Urol 2013;63 (6):986–94.

8. Hori S., Blanchet J. S., McLoughlin J. From prostate-specific antigen (PSA) to precursor PSA (proPSA) isoforms: a review of the emerging role of proPSAs in the detection and management of early prostate cancer. BJU Int 2013;112(6):717–28.

9. Heidegger I., Klocker H., Steiner E. et al. [-2]proPSA is an early marker for prostate cancer aggressiveness. Prostate Cancer Prostatic Dis 2013;1–5.

10. Собин Л. Х., Господарович М. К., Виттекинд К. TNM. Классификация злокачественных опухолей. М., 2011. [Sobin L. Kh., Gospodarovich M. K., Wittekind K. TNM. Malignant tumour classification. Moscow, 2011. (In Russ.)].

11. Stephan C., Vincendeau S., Houlgatte A. et al. Multicenter evaluation of [-2] proprostate-specific antigen and the prostate health. Clin Chem 2013;59(1):306–14.